8-K: Outlook Therapeutics Eyes European Launch and US BLA Resubmission for Wet AMD Treatment

Outlook Therapeutics reports its first fiscal quarter 2025 results, highlighting progress towards commercializing LYTENAVA in Europe and resubmitting its BLA in the US for wet AMD treatment.

Summary

• Outlook Therapeutics announced its financial results for the first quarter of fiscal year 2025, ended December 31, 2024.
• The company is on track to resubmit its Biologics License Application (BLA) for ONS-5010 in Q1 CY2025 for the treatment of wet age-related macular degeneration (wet AMD).
• Initial commercial launches of LYTENAVA (bevacizumab gamma) in Germany and the UK are planned for Q2 CY2025.
• The European Commission granted Marketing Authorization for LYTENAVA in the EU in May 2024, and the UK MHRA granted authorization in July 2024.
• Net income attributable to common stockholders for the quarter was $17.4 million, or $0.72 per share, compared to a net loss of $11.2 million, or $0.86 per share, for the same period last year.
• Adjusted net loss attributable to common stockholders was $21.6 million, or $0.89 per share, compared to $10.1 million, or $0.78 per share, for the same period last year.
• As of December 31, 2024, Outlook Therapeutics had cash and cash equivalents of $5.7 million, excluding $17.8 million received in January 2025 from a warrant exercise inducement.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in Europe and the BLA resubmission plans, but concerns remain about the adjusted net loss and cash position.

Positives

• LYTENAVA has received marketing authorization in the EU and UK, paving the way for commercial launch.
• The company is on track to resubmit the BLA for ONS-5010 in the US.
• Net income attributable to common stockholders for the quarter was $17.4 million, a significant improvement compared to the net loss of $11.2 million for the same period last year.
• NICE recommended LYTENAVA as an option for the treatment of wet AMD.

Negatives

• Adjusted net loss attributable to common stockholders was $21.6 million, higher than the $10.1 million for the same period last year.
• Cash and cash equivalents were $5.7 million as of December 31, 2024, which may raise concerns about the company's short-term financial stability.

Risks

• The resubmission of the BLA for ONS-5010 is subject to FDA approval, and there is no guarantee of a positive outcome.
• Commercial launch in Europe depends on successful market access and distribution.
• The company's financial performance is subject to risks associated with developing and commercializing pharmaceutical product candidates.
• The company's cash position may require additional financing in the future.

Future Outlook

Outlook Therapeutics anticipates beginning to generate revenue with the launch of LYTENAVA in Germany and the UK in Q2 CY2025 and expects potential US FDA approval of ONS-5010 in Q3 CY2025.

Management Comments

• Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics, commented that the company expects to be a very different company by the end of 2025.
• Kenyon stated that the company plans to start realizing its goal of providing patients, physicians, and payers with an approved ophthalmic formulation of bevacizumab in 2025.

Industry Context

Outlook Therapeutics is aiming to capture a portion of the wet AMD treatment market by offering an approved ophthalmic formulation of bevacizumab, LYTENAVA, as an alternative to off-label repackaged bevacizumab, particularly in Europe where its use is prevalent.

Comparison to Industry Standards

• The document mentions ranibizumab (Lucentis) as a comparator in the NORSE EIGHT trial, a standard treatment for wet AMD.
• The company is positioning LYTENAVA as a cGMP produced bevacizumab, which could be a differentiator compared to off-label repackaged bevacizumab.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the success of its regulatory and commercialization efforts.
• Patients with wet AMD could benefit from having access to an approved ophthalmic formulation of bevacizumab.
• Retina specialists will have a new treatment option for wet AMD.

Next Steps

• Resubmit the ONS-5010 BLA to the FDA in Q1 CY2025.
• Initiate commercial launches of LYTENAVA in Germany and the UK in Q2 CY2025.
• Pursue potential FDA approval of ONS-5010 in Q3 CY2025.
• Seek authorization in other European countries, Japan, and elsewhere.

Key Dates

Keywords

LYTENAVA, ONS-5010, wet AMD, bevacizumab, Outlook Therapeutics, BLA, FDA, commercial launch, retina, ophthalmic